Evidence map›Paper›PMID 37021426›Full record

ArticleInfection & chemotherapy2023

High Frequency of

Reza Ghotaslou, Behnaz Salahi, Ghazal Naderi, Naser Alizadeh

Open access · goldAbstract read
In one paragraph

Article in Infection & chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Reza GhotaslouImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0003-4762-3558
Behnaz SalahiRazi Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-6672-1922
Ghazal NaderiDivision of Microbiology, Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-0750-7707
Naser AlizadehZanjan Applied Pharmacology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran . alizadeh.n@zums.ac.ir.ORCID https://orcid.org/0000-0001-7616-9863
Tabriz University of Medical Sciences · IRTehran University of Medical Sciences · IRZanjan University of Medical Sciences · IR

Funding

Immunology Research Center, Tabriz University of Medical Sciences 1397.03
6 · The paper itself

Abstract

backgroundMATERIALS AND

methodsA total of 50 non-duplicated CRKP from January 2020 to December 2020 were isolated form Sina and Imam Reza Hospitals in Tabriz, Iran. Antimicrobial susceptibility testing was performed by the disk-diffusion method. The carbapenem resistance mechanisms were determined by the phenotypic and PCR procedures. CRKP isolates were typed by the Random Amplified Polymorphic DNA PCR (RAPD-PCR) technique.

resultsAmikacin was the most effective antibiotics against CRKP isolates. AmpC overproduction was observed in five CRKP isolates. Efflux pump activity was found in one isolate by the phenotypic method. Carba NP test could find carbapenemases genes in 96% of isolates. The most common carbapenemases gene in CRKP isolates were

conclusionThe

Indexed as

CarbapenemaseRandom Amplified Polymorphic DNA PCR

Identifiers

PMID37021426
PMCPMC10079451
OpenAlexW4352978522

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.